Molecular genetics of cancer susceptibility

Pharmacology

Volumn 61, Issue 3, 2000, Pages 212-227

  Brockmöller, Jürgen ^a   Cascorbi, Ingolf ^b   Henning, Stefan ^a   Meisel, Christian ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Arylamine N acetyltransferase; Cancer; Cytochrome P450; DNA repair; Glutathione S transferase; MDR1; Molecular epidemiology; Myeloperoxidase; Pharmacogenetics; Pharmacogenomics; Polymorphism

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CELL DNA; CYTOCHROME P450 1B1; CYTOCHROME P450 ISOENZYME; ETHOXYRESORUFIN DEETHYLASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; ISOENZYME; ISOPROTEIN; MULTIDRUG RESISTANCE PROTEIN; MYELOPEROXIDASE; PHENACETIN O DEETHYLASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ACETYLATOR PHENOTYPE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER THERAPY; CELL GROWTH; COLON CARCINOMA; DNA REPAIR; ENZYME POLYMORPHISM; GENETIC EPIDEMIOLOGY; GROWTH REGULATION; HUMAN; LARYNX CARCINOMA; LUNG CARCINOMA; METHODOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; XENOBIOTIC METABOLISM;

EID: 0343714817     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028403     Document Type: Review

References (73)

1. Perera FP, Weinstein IB: Molecular epidemiology and carcinogen-DNA adduct detection: New approaches to studies of human cancer causation. J Chron Dis 1982;35:581-600.
2. Kellerman G, Shaw CR, Luyten-Kellerman M: Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 1973; 289:934-937.
3. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR: Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984;312:169-170.
4. Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT: N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology: Preliminary results in Sweden and Denmark. Environ Health Perspect 1979;29:71-79.
5. Roots I, Brockmöller J, Drakoulis N, Loddenkemper R: Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients. Clin Invest 1992;70:307-319.
6. Caporaso N, Goldstein A: Cancer genes: single and susceptibility: Exposing the difference. Pharmacogenetics 1995;5:59-63.
7. Miller JA, Miller EC: Metabolic activation and reactivity of chemical carcinogens. Mutat Res 1975;33:25-26.
8. Caporaso N, Landi MT, Vineis P: Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics 1991;1:4-19.
9. Idle JR, Armstrong M, Boddy AV, Boustead C, Cholerton S, Cooper J, Daly AK, Ellis J, Gregory W, Hadidi H, et al: The pharmacogenetics of chemical carcinogenesis (see comments). Pharmacogenetics 1992;2:246-258.
10. Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J, Boffettta P: Metabolic Polymorphisms and Susceptibility to Cancer. Lyon, International Agency for Research on Cancer, 1999, vol 148.
11. Houlston R: CYP1A1 polymorphisms and lung cancer risk: A meta-analysis. Pharmacognetics 2000;10:105-114.
12. Brockmöller J, Cascorbi I, Kerb R, Sachse C, Roots I: Polymorphisms in xenobiotic conjugation and disease predisposition. Toxicol Lett 1998;102-103:173-183.
13. Hill AB: The environment and disease: association or causation. Proc R Soc Med 1965;58: 295-300.
14. Kerb R, Brockmöller J, Sachse C, Roots I: Detection of the GSTMI*0 allele by long polymerase chain reaction. Pharmacogenetics 1999;9:89-94.
15. Sprenger R, Schlagenhaufer R, Kerb R, Bruhn C, Brockmöller J, Roots I, Brinkmann U: Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics 2000;10:in press.
16. Harrison DJ, Cantlay AM, Rae F, Lamb D, Smith CA: Frequency of glutathione S-translferasc M1 deletion in smokers with emphysema and lung cancer. Hum Exp Toxicol 1997;16: 356-360.
17. Helzlsouer KJ, Selmin O, Huang HY, Strickland PT, Strickland PT, Hoffman S, Alberg AJ, Watson M, Comstock GW, Bell D: Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer (see comments). J Natl Cancer Inst 1998;90:512-518.
18. Kelsey KT, Hankinson SE, Colditz GA, Springer K, Garcia-Closas M, Spiegelman D, Manson JE, Garland M, Stampfer MJ, Willett WC, Speizer FE, Hunter DJ: Glutathione S-transferase class mu deletion polymorphism and breast cancer: Results from prevalent versus incident cases. Cancer Epidemiol Biomarkers Prev 1997;6:511-515.
19. Amhrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, Laughlin R, Nemoto T, Michalek AM, Harrington A, et al: Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995;55:3483-3485.
20. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF: Breast cancer and CYP1a1, GSTM1, and GSTT1 polymorphisms: Evidence of a lack of association in Caucasians and African Americans. Cancer Res 1998;58: 65-70.
21. Charrier J, Maugard CM, Le Mevel B, Bignon YJ: Allelotype influence at glutathione S-transferase M1 locus on breast cancer susceptibility. Br J Cancer 1999;79:346-353.
22. Ambrosone CB, Coles BF, Freudenheim JL, Schields PG: Glutathione-S-transferase (GSTM1) genetic polymorphisms do not affect human breast cancer risk, regardless of dietary antioxidants. J Nutr 1999;129(2S suppl):565S-568S.
23. Marcus PM, Vineis P, Rothman N: NAT2 slow acetylation and bladder cancer risk: A metaanalysis of 22 case-control studies conducted in the general population. Pharmacogenetics 2000;10:115-122.
24. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, Branch RA, Brockmöller J, Ishizaki T, Karakaya AE, Ladero JM, Mommsen S, Okkels H, Romkes M, Roots I, Rothman N: Cigarette smoking, N-acctyltransfcrase 2 acetylation status, and bladder cancer risk: A case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000;9:461-467.
25. Brockmöller J, Cascorbi I, Kerb R. Roots I: Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996;56:3915-3925.
26. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G, et al: Genetically based N-acetyltransferasc metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994;369: 154-156.
27. Cascorbi I, Brockmöller J, Mrozikicwicz PM, Müller A, Roots I: Arylamine N-acetyltransferase activity in man. Drug Metab Rev 1999;31: 489-502.
28. Shimizu Y, Nakatsuru Y, Ichinose M, Takahashi Y, Kume H, Mimura J, Fujii-Kuriyama Y, Ishikawa T: Benzo(a)pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 2000;97:779-782.
29. Cascorbi I, Brockmöller J, Roots I: A C4887A polymorphism in cxon 7 of human CYP1A1: Population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996;56:4965-4969.
30. Kristensen VN, Borresen-Dale AL: Molecular epidemiology of breast cancer: Genetic variation in steroid hormone metabolism. Mutat Res 2000;462:323-333.
31. Watanabe J, Shimada T, Gillam EM, Ikuta T, Suemasu K, Higashi Y, Gotoh O, Kawajiri K: Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 2000;10:25-33.
32. Zheng W, Xie DW, Jin F, Cheng JR, Dai Q, Wen WQ, Shu XO, Gao YT: Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2000;9:147-150.
33. McFayden MC, Breeman S, Payne S, Stirk C, Miller ID, Melvin WT, Murray GI: Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem 1999;47:1457-1464.
34. Buters JT, Sakai S, Richter T, Pineau T, Alexander DE, Savas U, Doehmer J, Ward JM, Jefcoate CR, Gonzalez FJ: Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA 1999;96:1977-1982.
35. Eltom SK, Larsen MC, Jefcoate CR: Expression of CYP1B1 but not CYP1A1 by primary cultured human mammary stromal fibroblasts constitutively and in response to dioxin exposure: role of the Ah receptor. Carcinogenesis 1998;19:1437-1444.
36. Sachse C, Brockmöller J, Bauer S, Roots I: Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-449.
37. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T: Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 1999;125: 803-808.
38. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T: Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 1999;90: 899-902.
39. Selsted ME, Miller CW, Novotny MJ, Morris WL, Koeffler HP: Molecular analysis of myeloperoxidase deficiency shows heterogeneous patterns of the complete deficiency state manifested at the genomic, mRNA, and protein levels. Blood 1993;82:1317-1322.
40. Cascorbi I, Henning S, Brockmöller J, Gephart J, Meisel C, Müller JM, Loddenkemper R, Roots I: Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant -463A of the myeloperoxidase gene. Cancer Res 2000;60:644-659.
41. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF: An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996; 271:14412-14420.
42. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V: An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 1997;90:2730-2737.
43. London SJ, Lehman TA, Taylor JA: Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997;57:5001-5003.
44. Schabath M, Spitz M, Zhang X, Delclos G, Wu X: Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis 2000;21: 1163-1166.
45. Le Marchand L, Seifried A, Luni A, Wilkens LR: Association of the myeloperoxidase -463G->a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000; 9:181-184.
46. Keppler D, Export pumps for glutathione S-conjugates. Free Radic Biol Med 1999;27:985-991.
47. Borst P, Evers R, Kool M, Wijnholds J: The multidrug resistance protein family. Biochim Biophys Acta 1999;1461:347-357.
48. Morrow CS, Smitherman PK, Townsend AJ: Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Biochem Pharmacol 1998;56:1013-1021.
49. Morrow CS, Diah S, Smitherman PK, Schneider E, Townsend AJ: Multidrug resistance protein and glutathione S-transferase P1-1 act in synergy to confer protection from 4-nitroquinoline 1-oxide toxicity. Carcinogenesis 1998; 19:109-115.
50. Brockmöller J, Kirchheiner J, Meisel C, Roots I: Pharmacogenctic diagnostics of cytochrome P450 polymorphisms. Pharmacogenomics 2000;1:125-151.
51. König J, Nies AT, Cui Y, Leier I, Keppler D: Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999;1461: 377-394.
52. Seelig A: A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 19987;251:251-261.
53. Seelig A, Blatter XL, Wohnsland F: Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison. Int J Clin Pharmacol Ther 2000; 38:111-121.
54. Van der Bliek AM, Baas F, Van der Velde-Koerts T, Biedler JL, Meyers MB, Ozols RF, Hamilton TC, Joenje H, Borst P: Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res 1988;48:5927-5932.
55. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichclbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-3478.
56. Kartenbeck J, Leuschner U, Mayer R, Keppler D: Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996;23:1061-1066.
57. Berwick M, Vineis P: Markers of DNA repair and susceptibility to cancer in humans: an epidemiological review. J Natl Cancer Inst 2000; 92:874-897.
58. Sturgis EM, Castillo EJ, Li L, Zheng R, Eicher SA, Clayman GL, Strom SS, Spitz MR, Wei Q: Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis 1999;20:2125-2129.
59. Gamcsik MP, Dolan ME, Andersson BS, Murray D: Mechanisms of resistance to the toxicity of cyclophosphamide. Curr Pharm Des 1999;5: 587-605.
60. Shen MR, Jones IM, Mohrenweiser H: Non-conservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998;58: 604-608.
61. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, Bell DA: XPD polymorphisms: Effects on DNA repair proficiency. Carcinogenesis 2000;21:551-555.
62. Lunn RM, Langlois RG, Hsich LL, Thompson CL, Bell DA: XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999;59: 2557-2561.
63. Price EA, Bourne SL, Radbourne R, Lawton PA, Lamerdin J, Thompson LH, Arrand JE: Rare microsatellite polymorphisms in the DNA repair genes XRCC1, XRCC3 and XRCC5 associated with cancer in patients of varying radiosensitivity. Somat Cell Mol Genet 1997;23:237-247.
64. Kaur TB, Traveline JM, Gaughan JP, Richie JP Jr, Stellman SD, Lazarus P: Role of polymorphisms in codons 143 and 160 of the O6-alkylguanine DNA alkyltransferase gene in lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:339-342.
65. Deng C, Xie D, Capasso H, Zhao Y, Wang LD, Hong JY: Genetic polymorphism of human O6-alkylguanine-DNA alkyltransferase: identification of a missense variation in the active site region. Pharmacogenetics 1999;9:81-87.
66. Imai Y, Oda H, Nakatsuru Y, Ishikawa T: A polymorphism at codon 160 of human O6-methylguanine-DNA methyltransferase gene in young patients with adult type cancers and functional assay. Carcinogenesis 1995;16: 2441-2445.
67. Sugimura H, Kohno T, Wakai K, Nagura K, Genka K, Igarashi H, Morris BJ, Baba S, Ohno Y, Gao C, Li Z, Wang J, Takezaki T, Tajima K, Varga T, Sawaguchi T, Lum JK, Martinson JJ, Tsugane S, Iwamasa T, Shinmura K, Yokota J: hOGC1 Ser326Cys polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1999;8:669-674.
68. Eydmann ME, Knowles MA: Mutation analysis of 8p genes POLB and PPP2CB in bladder cancer. Cancer Genet Cytogenet 1997;93:167-171.
69. Dobashi Y, Kubota Y, Shuin T, Torigoe S, Yao M, Hosaka M: Polymorphisms in the human DNA polymerase beta gene. Hum Genet 1995; 95:389-390.
70. Fan F, Liu C, Tavare S, Arnheim N: Polymorphisms in the human DNA repair gene XPF. Mutat Res 1999;406:115-120.
71. Roots I, Drakoulis N, Ploch M, Heinemeyer G, Loddenkemper R, Minks T, Nitz M, Otte F, Koch M: Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Klin Wochenschr 1988;(suppl 11):87-97.
72. Kaisary A, Smith P, Jaczq E, McAllister CB, Wilkinson GR, Ray WA, Branch RA: Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987;47:5488-5493.
73. Perera FP, Weinstein IB: Molecular epidemiology: Recent advances and future directions. Carcinogenesis 2000;21:517-524.